| Azacitidine and Homoharringtonine in JMML | Efficacy of Concomitant Use of Azacitidine and Homoharringtonine in Children With Juvenile Myelomonocytic Leukemia | NCT04505995 |
| To evaluate the exploratory clinical trial of homoharringtonine in the treatment of adult COVID-19 patients | To evaluate the exploratory clinical trial of homoharringtonine in the treatment of adult COVID-19 patients | ChiCTR2100045993 |
| Cladribine, homoharringtonine and cytarabine (CHA) regimen in the treatment of refractory/relapsed acute myeloid leukemia | A single center, single-arm, prospective clinical study of Cladribine, homoharringtonine and cytarabine (CHA) regimen in the treatment of refractory/relapsed acute myeloid leukemia | ChiCTR-OPC-14005712 |
| Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced Chronic Myeloid Leukemia | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate; OMA) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) Who have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy | CTRI/2013/11/004124 |
| An open-label, randomized, phase III trial of homoharringtonine in the treatment of subjects with newly diagnosed acute promyelocytic leukemia | Study on optimization and strategy for treatment of major hematologic diseases | ChiCTR-TRC-12002628 |
| Efficacy and Safety of CHG Regimen in Treatment of High-risk MDS and MDS-AML | Efficacy and Safety Study of CHG Regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) in the Treatment of High-risk Myelodysplastic Syndromes(MDS) and Acute myeloid Leukemia Transformed | ChiCTR-ONC-11001501 |
| Clinical study for the treatment of aged acute myeloid leukemia by azacytidine combined with homoharringtonine | Clinical study for the treatment of aged acute myeloid leukemia by azacytidine combined with homoharringtonine | ChiCTR1900021315 |
| A multiple center and prospective clinical study of low dose of venetoclax combined with low dose of cytarabine and homoharringtonine in the treatment of newly diagnosed acute myeloid leukemia and myelodysplastic syndrome EB-2 over 60 years old or ineligible for intensive chemotherapy | A multiple center and prospective clinical study of low dose of venetoclax combined with low dose of cytarabine and homoharringtonine in the treatment of newly diagnosed acute myeloid leukemia and myelodysplastic syndrome EB-2 over 60 years old or ineligible for intensive chemotherapy | ChiCTR2200056676 |
| Safety and efficacy of Homoharringtonine (HHT) inhalation combined with PD-1 monoclonal antibody in the treatment of advanced tumor with lung metastases | Safety and efficacy of Homoharringtonine (HHT) inhalation combined with PD-1 monoclonal antibody in the treatment of advanced tumor with lung metastases | ChiCTR2100049182 |
| Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined with Androgen Deprivation for Prostate Cancer | A Randomized Controlled Study of Homoharringtonine Combined with Androgen Deprivation in Neoadjuvant Therapy for Prostate Cancer | NCT06834321 |
| Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. | Efficacy and Safety of Venetoclax and Azacitidine Combined With Low-Intensity Homoharringtonine Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate/High-Risk Newly Diagnosed Acute Myeloid Leukemia | NCT06483906 |
| Therapeutic role of homoharringtonine in acute promyelocytic leukemia, an open label randomised controlled trial | An open randomised trial of therapeutic role of homoharringtonine in acute promyelocytic leukemia | ChiCTR-TRC-09000504 |
| Efficacy and safety of chemotherapy using homoharringtonine combined with Venetoclax in the treatment of AML and high-risk MDS: a prospective, multi-center clinical study | Efficacy and safety of chemotherapy using homoharringtonine combined with Venetoclax in the treatment of AML and high-risk MDS: a prospective, multi-center clinical study | ChiCTR2400080047 |
| Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia | A Monocenter Prospective Single Arm Study of Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for Induced Therapy in Adults de Novo Acute Myeloid Leukemia (Non-M3) | NCT05906914 |
| Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | Venetoclax in Combination With Homoharringtonine and Cytarabine in Newly Diagnosed Subjects With Acute Myeloid Leukemia: a Phase 2/3, the Single-arm, Open-label, Monocentric Study | NCT05805098 |
| Efficacy and safety study of Venetoclax in combination with high dose of Decitabine and Homoharringtonine(DEC3-VEN-HHT)as therapy for newly diagnosed patient acute myeloid leukemia with RUNX1 / RUNX1TI, CBFB/MYH11 mutation( a phase 2, multicenter, single-arm trial) | Efficacy and safety study of Venetoclax in combination with high dose of Decitabine and Homoharringtonine(DEC3-VEN-HHT)as therapy for newly diagnosed patient acute myeloid leukemia with RUNX1 / RUNX1TI, CBFB/MYH11 mutation( a phase 2, multicenter, single-arm trial) | ChiCTR2500101192 |
| Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy | NCT00462943 |
| A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) | An Open-Label, Single-Group Clinical Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Mepesuccinate Given Subcutaneously as a Fixed Dose inPatients With Chronic Phase or Accelerated Phase Chronic Myeloid Leukemia Who Have Failed 2 or More Tyrosine Kinase Inhibitor Therapies | NCT02078960 |
| A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Refractory or Relapsed Acute Myeloid Leukemia (AML) | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Refractory or Relapsed Acute Myeloid Leukemia (AML) | EUCTR2006-004517-17-FR |
| Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | PHASE II STUDY OF SIMULTANEOUS HOMOHARRINGTONINE (NSC 141633) AND ALPHA INTERFERON (IFN-A) THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA (CML) | NCT00002574 |
| Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | Phase I and Pilot Study of Subcutaneous Homoharringtonine in Chronic Myelogenous Leukemia | NCT00006364 |
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate | An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors | NCT01844869 |
| Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age | NCT02029417 |
| Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD | A Phase II Single-arm Open-labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | NCT03135054 |
| Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | A Phase II Single-arm Open-labeled Study Evaluating Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | NCT03170895 |
| An Open Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]c in Patients with Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors. | An Open Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]c in Patients with Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors. - TEVA C41443/1103 | NL-OMON40403 |
| Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | A Phase III Study of Interferon-Refractory Patients With BCR/ABL(+) Chronic Myelogenous Leukemia (CML) Treated With Homoharringtonine (NSC #141633) vs. Hydroxyurea | NCT00004933 |
| Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia | A Phase I/II Open-Label Study Of The Intravenous Administration Of Homoharringtonine (CGX-635) Salvage Therapy For The Treatment Of Refractory Acute Promyelocytic Leukemia | NCT00030355 |
| Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | A Phase II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Combined With the Oral Administration of Gleevec in the Treatment of Patients With Chronic Myeloid Leukemia (CML) in Chronic, Accelerated, and Blast Phase | NCT00114959 |
| A phase II, multicentre, open-label, single arm, extension study of maintenancetreatment with subcutaneous homoharringtonine (HHT) as a single agent inpatients with chronic myeloid leukemia (CML) who received HHT in study HHT-CML/INTL/04.2 and have achieved a complete hematological response (CHR)or returned to chronic phase. | A phase II, multicentre, open-label, single arm, extension study of maintenancetreatment with subcutaneous homoharringtonine (HHT) as a single agent inpatients with chronic myeloid leukemia (CML) who received HHT in study HHT-CML/INTL/04.2 and have achieved a complete hematological response (CHR)or returned to chronic phase. | EUCTR2005-000814-11-GB |
| A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine) (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine) (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation | EUCTR2006-000176-32-DE |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine. (Omacetaxine) (CGX-635) in the Treatment of Patients With Chronic Myeloid Leukemia. (CML) With the T315I BCR-ABL Gene Mutation | NCT00375219 |
| Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT) | NCT00003239 |
| Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | A Phase II Study of Newly Diagnosed Patients With BCR/ABL (+) Chronic Myelogenous Leukemia Treated With Combined Homoharringtonine (NSC #141633) and Low-Dose Cytarabine | NCT00003694 |
